AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03728855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administration of medication (SAM)
Description: Patients use medication from their own stock, self-administered.
Study NCT05965453 — intervention group
Intervention type: DEVICE
Intervention: the Castor single branch stent graft
Description: Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
Study NCT02792660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injeq IQ-Needle
Description: Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
Study NCT01257672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ondansetron syrup (0,15 mg/Kg of body weight)
Study NCT01257672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: domperidone syrup (0,5 mg/Kg of body weight)
Study NCT01257672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02139267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-188E
Description: DNA vaccine administered via IM route using TDS-IM electroporation device
Study NCT03127852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medly
Study NCT02123394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
Study NCT02123394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie method
Description: The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
Study NCT02283983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mittens and booties
Study NCT02283983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cooling helmet
Study NCT01830244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
Study NCT03304912 — intervention group
Intervention type: BEHAVIORAL
Intervention: PrEP Education and option to accept a PrEP prescription
Description: Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
Study NCT03869216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Shared Decision-Making Intervention
Description: The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
Study NCT04412772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.
Study NCT04412772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
Study NCT02418728 — intervention group
Intervention type: OTHER
Intervention: subcutaneous adipose tissue microdialysis under local beta/alpha blockade
Description: adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
Study NCT01135394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
Study NCT03968081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyberball
Description: a ball tossing playing game in which the experimentor can control the number of throws received by the participants
Study NCT03968081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cyberball
Description: a ball tossing playing game in which the experimentor can control the number of throws received by the participants
Study NCT01614340 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-Behavioral Pain Self-management Program
Description: The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
Study NCT02392676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLAPARIB
Description: Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study NCT02392676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study NCT03914651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
Description: On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
Study NCT03914651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
Description: On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
Study NCT02866903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Description: Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
Study NCT02866903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Description: systemic FOLFIRI chemotherapy
Study NCT02866903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Description: bevacizumab
Study NCT01313039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ6244
Description: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
Study NCT04705610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-oculography / Social cognition tasks / Neuropsychological evaluations
Description: * Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~* Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~* Neurological evaluation~* Neuropsychological evaluations~* Social cognitions tasks~* Behaviour assessment
Study NCT00639262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
Study NCT00639262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: For Cohort 2 - Gliomas only.
Study NCT00639262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation Therapy (XRT)
Study NCT02688153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDWARDS INTUITY
Description: To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR \& CABG.
Study NCT02688153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stented aortic bioprostheses
Description: In comparison to control valves available on the market.
Study NCT04480346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program
Description: Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
Study NCT00779363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rechargeable TANTALUS II
Description: Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
Study NCT05248529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education booklet
Description: Hip/Knee Replacement Adaptation Booklet explains preoperative preparation, post-operative care practices, how to walk with walker, what needs to be done at home after discharge
Study NCT03224260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension
Study NCT03224260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Placebo
Description: Oral Suspension
Study NCT04236219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-346
Description: ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
Study NCT04236219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
Study NCT03654560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HemoStyp
Description: During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
Study NCT03654560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel
Description: During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
Study NCT01789749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snare Tip Soft Coagulation
Study NCT01789749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Snare Tip Soft Coagulation
Study NCT02108223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fix dose r-FSH (Gonal-f)
Description: recombinant follicle stimulation
Study NCT02108223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-LH supplementation
Description: recombinant luteinizing hormone
Study NCT02108223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-FSH (Gonal-f)
Description: recombinant follicle stimulation hormone
Study NCT03962634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovanaze Nasal Spray
Description: Intra-nasal local anesthetic
Study NCT03962634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Injection
Description: Local anesthetic
Study NCT00704392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL647
Description: Tablets supplied at 50-mg strength administered orally daily
Study NCT00704392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147
Description: Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
Study NCT01063504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: teriparatide
Study NCT01063504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Study NCT04695418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice Germ
Description: The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
Study NCT04695418 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
Study NCT01255189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: near infrared spectroscopy: INVOS 5100
Description: NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
Study NCT01255189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: invos 5100
Description: near infrared spectroscopy: invos 5100
Study NCT02667028 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention
Study NCT01766245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
Study NCT01766245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
Study NCT01597440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-carbamylglutamate
Description: Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner).
Study NCT01597440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care
Study NCT01597440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT02809118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-111 0.4 mg/ml
Description: AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
Study NCT02809118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-111 0.8 mg/ml
Description: AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
Study NCT02809118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel is administered with a single dose into the affected ear after topical anesthesia
Study NCT00798473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
Study NCT00798473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV saline infusion
Study NCT01591993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10% lactic acid test
Description: To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
Study NCT01591993 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
Study NCT04055844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
Study NCT04055844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to >100 x 10\^9/L.
Study NCT04055844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
Study NCT02680106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPINNER
Description: The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.
Study NCT02680106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JELONET / IBU Biatain
Description: The patient's DSW will be dressed by JELONET/IBU Biatain
Study NCT02429349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
Study NCT00481221 — intervention group
Intervention type: PROCEDURE
Intervention: Observation of results from laboratory tests
Description: Laboratory data summary only
Study NCT03346291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling
Description: individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
Study NCT05434936 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oophorectomy
Description: Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
Study NCT02091193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Krill Oil (Supplement A)